
 | C·¿ËýÀ´Î±ê¤Î²¹Ç®ÎÅË¡¤Ë¤è¤ë´ÎÁÈ¿¥Æâ°äÅÁ»Òȯ¸½¤ÎÊѲ½ ¢¡ | ¡ú²¹Ç®¼£ÎÅÆÃÀß Â¾ |
 |
 | C·¿ËýÀ´Î±ê·Ð²áÃæ¤Ëȯ¾É¤·¤¿ç¹°À¥ê¥ó¥Ñ¼ð¤Î1˶¸¡Îã ¢¡ | °À¥ê¥ó¥Ñ¼ð ¾ |
 |
 | C·¿ËýÀ´Î±ê¸¦µæ¤Î¿ÊÊâ¤ÈŸ˾¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡ | ´Î±ê ¾ |
 |
 | Danenberg Tumor ProfileË¡¤Ë¤è¤ëÂçIJ´â¤Ë¤ª¤±¤ëTS¤ª¤è¤ÓDPD mRNAȯ¸½Î̤θ¡Æ¤ ¢¡ | ÂçIJ´â ¾ |
 |
 | Degradable starch microspheres (DSM) Ê»ÍÑ´ÎÆ°Ì®²½³ØºÉÀòÎÅË¡ (DSM-TACE) ¤¬Ãø¸ú¤·¤¿, ²¼ÂçÀÅÌ®¤ª¤è¤ÓÌçÌ®¼ðáçºÉÀò¤ò¤È¤â¤Ê¤¦¤Ó¤Þ¤ó·¿´ÎºÙ˦´â¤Î1Îã ¢¡ | ´Î¡´â ¾ |
 |
 | DIC ¿ÇÃÇ´ð½à¤ÎÊÑÁ«¡¡¡¡¡¦¡¦¡¦DIC¤Î¿ÇÃÇ
DlC¤Î³µÇ°¡¦ÄêµÁ
DIC¤Î³µÇ°¡¦¿ÇÃǤÎÊÑÁ«¡¡¿ÇÃÇ´ð½à¤ÎÈæ³Ó¡¡¡¦¡¦ ¢¡ | DIC ¾ |
 |
 | DIC¤Ë¤ª¤±¤ë¿·¤·¤¤¹³¶Å¸ÇÌô¤Î»È¤¤Ê¬¤±¡¡¡¦¡¦¡¦Äãʬ»Òheparin ºîÍѵ¡½ø¡¡ÌôÍýºîÍÑ¡¡
¥Ø¥Ñ¥ê¥Î¥¤¥É¡¡¡¦¡¦ ¢¡ | DIC ¾ |
 |
 | DIC¤Î¸¡ºº¤Îή¤ì¤ÈÆÉ¤ßÊý¡¡¡¦¡¦¡¦DIC¤Î¸¡ºº ·ì¾®ÈÄ¿ô ¥×¥í¥È¥í¥ó¥Ó¥ó»þ´ÖÈæ
·ìÞù¥Õ¥£¥Ö¥ê¥Î¥²¥óÃÍ¡¡FDP¡¡·ì¾®ÈÄ¿ô¡¦¡¦ ¢¡ | DIC ¾ |
 |
 | DIC¤òʻȯ¤·MTX/5-FU¸òÂåÎÅË¡¤¬ÁÕ¸ú¤·¤¿¿Ê¹Ô°ß´â¤Î1Îã ¢¡ | DIC ¾ |
 |
 | ¢¡3729 | ²½³ØÎÅË¡ ¾ |
 |
 | DlC¤Îɰø¤ÈÎ×¾²ÉÂÂ֤οÍÍÀ¡¡¡¦¡¦¡¦DIC¤Îɰø¤ÈÎ×¾²¾É¾õ¤Î´ØÏ¢¡¡
´ðÁüÀ´µÊ̤ÎDICȯ¾Éµ¡½ø¡¡
¡¡ÇÔ·ì¾É¡¡¸Ç·Á¼ðáç¡¡µÞ¡¦¡¦ ¢¡ | DIC ¾ |
 |
 | DlC¼£ÎŤδðËÜ¡¡¡Ý DlC¤Î¼£ÎÅ¡¡¡¦¡¦¡¦¹³¶Å¸ÇÎÅË¡
heparin À®ÃÁÇòʬ²ò¹ÚÁÇÁ˳²Ìô FOY
¹³ÀþÍÏÎÅË¡¡¡
Êä½¼¡¦¡¦ ¢¡ | DIC ¾ |
 |
 | DMpCÎÅË¡¤¬°Ý»ýÎÅË¡¤È¤·¤ÆÍ¸ú¤Ç¤¢¤Ã¤¿¿Ê¹ÔºÆÈ¯Æý´â¤Î1Îã ¢¡ | Æý´â ¾ |
 |
 | DNA¥Á¥Ã¥×¤òÍѤ¤¤¿Ê¢ËìÇżï¿ÇÃǤΤ¿¤á¤Î¿·µ¬¥Þ¡¼¥«¡¼¤Îõº÷ ¢¡ | ´âÀÊ¢Ëì±ê ¾ |
 |
 | DNA¥È¥Ý¥¤¥½¥á¥é¡¼¥¼Á˳²³èÀ¤Î¸¡Äê¡¡¡¦¡¦¡¦¹³¤¬¤óºÞõº÷¤Î¥Ð¡¼¥Á¥ã¥ë¸¦µæ½ê¡¼Ê¸Éô¾Ê¤¬¤óÆÃÄêÎΰ踦µæ¤Ë¤ª¤±¤ë¹³¤¬¤óºÞ¥¹¥¯¥ê¡¼¥Ë¥ó¥°¡¼¡¦¡¦ ¢¡ | ²½³ØÎÅË¡ ¾ |
 |
 | DNA¥á¥Á¥ë²½¤È´â-²½³ØÎÅË¡¤ÎɸŪ¤È¤·¤Æ- | 30-13 |
 |
 | Docetaxel (TXT) Medroxyprogesterone Acetate (MPA)¤ÎÊ»ÍѤˤè¤ê´°Á´´²²ò¤¬ÆÀ¤é¤ì¤¿Æý´â½Ñ¸å¿ȯÀÇÙž°Ü¤Î1Îã ¢¡ | Æý´â ¾ |
 |
 | Docetaxel(TXT)¤Î½ÑÁ°Æ°ÃíÎÅË¡¤òÃæ¿´¤È¤·¤¿½¸³ØÅª¼£ÎŤ¬ÁÕ¸ú¤·¤¿¶É½ê¿Ê¹ÔÆý´â¤Î1Îã ¢¡ | Æý´â ¾ |
 |
 | Docetaxel+5'-DFURÊ»ÍѲ½³ØÎÅË¡¤¬Ãø¸ú¤·¤¿ºÆÈ¯°ß´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | Docetaxel+PrednisoloneÎÅË¡¤¬Ãø¸ú¤·¼ðáçÇ®¤¬·Ú²÷¤·¤¿¥Û¥ë¥â¥óÄñ¹³ÀÁ°Î©Á£´â¤Î1Îã | 33-06 |
 |
 | Docetaxel+TS-1Ê»ÍÑÎÅË¡¤¬ÁÕ¸ú¤·¤¿Â¿È¯À¹üž°Ü,Ê¢ËìÇżï¤òȼ¤¦»Ä°ß´â¤Î1Îã ¢¡ | ¹üž°Ü ¾ |
 |
 | Docetaxel,Cisplatin,5-FU Regimen2¥¯¡¼¥ë¸å¤ËÊü¼ÍÀþ¾È¼ÍÎÅË¡¤òÊ»ÍѤ·¤¿²¼°öƬ´â4¾ÉÎã ¢¡ | °öƬ´â ¾ |
 |
 | Docetaxel,Cisplatin,5-FU,l-Leucovorin¤ËÁÕ¸ú¤·¤¿Ãæ°öƬ´âÇÙž°Ü¾ÉÎã ¢¡ | °öƬ´â ¾ |
 |
 | Docetaxel,Cisplatin,5-FU,Levofolinate¤òÍѤ¤¤¿²½³ØÎÅË¡¤ÇCR¤òÆÀ¤¿²¼°öƬ´â¤Î1Îã | 29-10 |
 |
 | Docetaxel,Ifosfamide,Cisplatin¤ËÁÕ¸ú¤·¤¿¶É½ê¿Ê¹ÔÃæ°öƬ´âÎã ¢¡ | £²·îÂ裳½µ¡§£±£¹Æü¡ÊÅÚ¡Ë Â¾ |
 |
 | Docetaxel/CyclophosphamideÊ»ÍÑÎÅË¡¤¬ÁÕ¸ú¤·¤¿Æý´â½Ñ¸å¿ȯÇÙž°Ü¤Î1Îã ¢¡ | ¶»Éô ¾ |
 |
 | Docetaxel/TS-1Ê»ÍÑÎÅË¡¤¬Í¸ú¤Ç¤¢¤Ã¤¿´âÀ¥ê¥ó¥Ñ´É¾É¤òȼ¤¦ÀÚ½üÉÔǽ¿Ê¹Ô°ß´â¤Î1Îã ¢¡ | £··îÂ裳½µ¡§£±£¶Æü¡ÊÅÚ¡Ë Â¾ |
 |
 | Docetaxel¡ÜDoxifluridine²½³ØÎÅË¡¤¬ÁÕ¸ú¤·¤¿°ß´âÈéɿž°Ü¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | Docetaxel¤¬Ãø¸ú¤·¤¿¹¢Æ¬´âÇÙž°Ü¾ÉÎã ¢¡ | ¹¢Æ¬´â ¾ |
 |
 | Docetaxel¤Ë¤è¤ëNeoadjuvant Chemotherapy¸åÊü¼ÍÀþ¼£ÎŤÇÀ©¸æ¤µ¤ì¤¿²¼°öƬ¸åÊÉ´â¾ÉÎã ¢¡ | °öƬ´â ¾ |
 |
 | Docetaxel¤Î·ìÃæ,Ê¢¿åÃæ¤ÎÌôʪưÂÖ¤ò¸¡Æ¤¤·¤¿°ß´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | Docetaxel¤ÎĶÁªÂòŪưÃíÎÅË¡¤¬Í¸ú¤Ç¤¢¤Ã¤¿¿Ê¹Ô²¼°öƬ´â¤Î1Îã ¢¡ | °öƬ´â ¾ |
 |
 | Docetaxel¤òÊ»ÍѤ·¤¿¿©Æ»´â¤ËÂФ¹¤ë²½³ØÊü¼ÍÀþÎÅË¡ ¢¡ | Êü¼ÍÀþ´ØÏ¢ ¾ |
 |
 | ¢¡3731 | ²½³ØÎÅË¡ ¾ |
 |
 | Docetaxel²½³ØÎÅË¡¤¬ÁÕ¸ú¤·ÀÚ½ü²Äǽ¤È¤Ê¤Ã¤¿stage IV°ß´â¤Î1Îã | 39-01 |
 |
 | Docetaxel´ÎưÃí¤ÈTrastuzumabÀÅÃí¤Ë¤è¤ëÊ»ÍѲ½³ØÎÅË¡¤¬ÁÕ¸ú¤·¤¿Æý´â´Îž°Ü¤Î1Îã | 31-09 |
 |
 | DocetaxelưÃíÊ»ÍÑÊü¼ÍÀþÎÅË¡¤ÇÎɹ¥¤Ê·Ð²á¤ò¤È¤Ã¤¿91ºÐ¾å³Ü´â¾ÉÎã ¢¡ | ¾å³Ü´â ¾ |
 |
 | Doxifluridine(5'-DFUR),Cyclophosphamide(CPA),Medroxyprogesteroneacetate(MPA)¤ÈPamidronate¡¡Disodium¤ÎÊ»ÍѤˤè¤êµÞ®¤Ë²þÁ±¤·¤¿Æý´â¹üž°Ü¤Î1Îã ¢¡ | ¹üž°Ü ¾ |
 |
 | Doxorubicin(adriamycin)¤ò°ÂÁ´¤Ë»ÈÍѤ·¤¨¤¿Marfan¾É¸õ·²¹çÊ»°Û»þξ¦Æý´â¤Î1Îã ¢¡ | 8·îÂ裴½µ¡¡£²£¶Æü ¾ |
 |
 | DPC¤È¤¬¤ó¿ÇÎÅ¡¡¡¦¡¦¡¦Êñ³çɾ²Á¤Î¿ÇÃÇ·²Ê¬Îà¡¡
°åÎÅÈñ¤Î»ÙʧÊýË¡¡¡
¼ÂºÝ¤Î»»ÄêÎã¡¡
¸½ºß¤ÎÊñ³ç»Ùʧ¤¤¤Ç¤ÎÌ䡦¡¦ ¢¡ | À©ÅÙ¡¦Ë¡Î§¡¦Åý·× ¾ |
 |
 | DPC¤È¥¯¥ê¥Æ¥£¥«¥ë¥Ñ¥¹¡¡¡¦¡¦¡¦¥¯¥ê¥Æ¥£¥«¥ë¥Ñ¥¹¤Î¸úÍÑ¡¡
´â¿ÇÎŤˤª¤±¤ë¥¯¥ê¥Æ¥£¥«¥ë¥Ñ¥¹¤Î±¿ÍÑ¡¡
¥¯¥ê¥Æ¥£¥«¥ë¥Ñ¥¹¤Î¡¦¡¦ ¢¡ | À©ÅÙ¡¦Ë¡Î§¡¦Åý·× ¾ |
 |
 | DPC»Ü¹Ô¤Ë¤è¤ë´â²½³ØÎÅË¡¤ÎÊѲ½¡¡¡¦¡¦¡¦Êñ³çÀè¿Ê°åÎÅ¥»¥ó¥¿¡¼¤Ø¤Î½¸Ãæ²½¡¡Á´¹ñ82»ÜÀß
¾Ã²½´ï´â¡¡
Æý´â
¹Í»¡¡¦¡¦ ¢¡ | À©ÅÙ¡¦Ë¡Î§¡¦Åý·× ¾ |
 |
 | Dukes'CÂçIJ´â¤ËÂФ¹¤ëͽËÉŪ´Îư̮²½³ØÎÅË¡¤ÎÀ®ÀÓ-¸¶È¯Áã¤ÎTS,DPD,p53¤ª¤è¤ÓOPRTȯ¸½¤È¤Î´Ø·¸- ¢¡ | ÂçIJ´â ¾ |
 |
 | Dxtran magnetite(DM)γ»Ò¤òÍѤ¤¤ëÁÈ¿¥ÆâͶƳ²Ã²¹Ë¡¤Î´ðÁäÈÎ×¾²±þÍÑ ¢¡ | 18-Supplement ¾ |
 |
 | Dynamic MRI¤¬ÍÍѤǤ¢¤Ã¤¿ÀøºßÀÆý´â¤Î1Îã ¢¡ | Æý´â ¾ |
 |
 | EBM¡¦(Evidence-Based Medicine) ¤È¤Ï¡© ¢¡ | DIC ¾ |
 |
 | EBM¤Ë´ð¤Å¤¤¤¿Å¾°ÜÀǾ¼ðáç¤Î¼£ÎÅ¡¡¡¦¡¦¡¦ÉÑÅÙ¡¡
ͽ¸å°ø»Ò
ñȯÀ¼ðáç¤ËÂФ¹¤ë¼£ÎÅ¡¡
¡¡³°²Ê¼ê½Ñ¡ÜÁ´Ç¾¾È¼Í¡¡Äê°ÌÊü¼ÍÀþ¾È¼Íñ¡¦¡¦ ¢¡ | Ǿ¼ðáç ¾ |
 |
 | EBM¤Ë´ð¤Å¤¯°ßÄÙáç¿ÇÎÅ¥¬¥¤¥É¥é¥¤¥ó¡¡¡¦¡¦¡¦¤Ï¤¸¤á¤Ë¡¡¡¡
µ.Evidence-based medicine(EBM)¤È°ßÄÙáç¿ÇÎÅ¡¦¡¦ | 62-07 |
 |
 | ECÎÅË¡(Epirubicin,Cyclophosphamide),Taxanes,Trastuzumab¼£ÎŸå¤ËUFT¤ÈCPAÊ»ÍÑÎÅË¡¤¬ÁÕ¸ú¤·¤¿HER2ÍÛÀºÆÈ¯Æý´â(ÇÙž°Ü)¤Î1Îã ¢¡ | Æý´â ¾ |
 |
 | Electrofusion¤Ë¤è¤ë¼ù¾õºÙ˦¤È¥Ò¥È°ß´âºÙ˦¤ÎÍ»¹çºÙ˦¤ÎºîÀ½¤ÈCTLͶƳ¤Î»î¤ß ¢¡ | °ß´â ¾ |
 |
 | Electrolyte depletion syndrome¤òÄ褷¤¿Ä¾Ä²å°ÌÓ¼ðáç¤Î1Îã | 39-02 |
 |
 | EMR¤ÎŬ±þ¤È¼£ÎÅÀ®ÀÓ¡¡¡¦¡¦¡¦¿ÇÃÇ¡¦¼£Îŵ»½Ñ¹ÖºÂ¡¡¡¡°ß´â¤ÎEMR¡ÝÂè1²ó
¡¡¡¡
¡¡1.ESDŬ±þÉÂÊѤÎÁªÂò¡¡
¡¡¡¦¡¦ ¢¡ | °ß´â ¾ |
 |
 | Endometriosis¤òÇØ·Ê¤È¤·¤¿ÍñÁã Carcinosarcoma¤Î1¾ÉÎã ¢¡ | 8·îÂ裴½µ¡¡£²£¶Æü ¾ |
 |
 | EORTC QOLÄ´ººÉ¼°ß´â´µ¼ÔÍѥ⥸¥å¡¼¥ëSTO22(ÆüËܸìÈÇ)¤Î³«È¯ ¢¡ | °ß´â ¾ |
 |
 | Estrogen Receptor¤ª¤è¤ÓProgesterone Receptor¬Äê¤Ë¤ª¤±¤ëDextran Charcoal Method¤ÈEnzyme Immunoassay´ÖÉÔ°ìÃ×°ø»Ò¤Î¸¡Æ¤ ¢¡ | Æý´â ¾ |
 |
 | Etoposide,Ara-C¾¯ÎÌ»ý³ÅÀÅ©ÎÅË¡¤ËMitoxantrone¤ò²Ã¤¨¤¿MEtAÎÅË¡¤Ë¤è¤ê´²²ò¤òÆÀ¤¿De Novo AML with Trilineage Myelodysplasia(AML/TMDS)¤Î5¾ÉÎã ¢¡ | Çò·ìÉ ¾ |
 |
 | Etoposide,Ifosfamide,Nedaplatin¤Ë¤è¤ë3ºÞÊ»ÍѲ½³ØÎÅË¡¤¬Ãø¸ú¤·¤¿¶»Á£´â¤Î1Îã ¢¡ | £··îÂ裳½µ¡§£±£¶Æü¡ÊÅÚ¡Ë Â¾ |
 |
 | Etoposide¤Ë¤è¤ë²áÉÒÈ¿±þ¤Î1Îã¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡ | ÍñÁã´â ¾ |
 |
 | EtoposideÆâÉþ¤¬Ãø¸ú¤·¤¿°ß¸¶È¯¤ÓÌ¡ÀÂçºÙ˦·¿BºÙ˦¥ê¥ó¥Ñ¼ð¤Î½Ñ¸åºÆÈ¯¤Î1Îã ¢¡ | £³·îÂ裳½µ¡§£±£¹Æü¡ÊÅÚ¡Ë Â¾ |
 |
 | EUS FNA¤Ç¿ÇÃǤ·, ưÃí²½³ØÎÅË¡¤¬Í¸ú¤Ç¤¢¤Ã¤¿AFP»ºÀ¸ç¹Á£Ë¼ºÙ˦´â¤Î1Îã ¢¡ | 9·î£²½µ¡Ê£¹Æü¡Ë ¾ |
 |
 | EUS, US¡¡¡¦¡¦¡¦EUS¤Ë¤è¤ëç¹´â¤ÎÁá´ü¿ÇÃÇ¡¿EUS¤Ë¤è¤ë¾¼À´µ¤È¤Î´ÕÊÌ¿ÇÃÇ¡¿EUS¤Ë¤è¤ëç¹´â¤ÎÉ´ü¿ÇÃÇ¡¿¡¦¡¦ | 76 |
 |
 | Evaluation of Cell Viability by Double-staining Fluorescence Assay | 29-11 |
 |
 | Evidence¤Ë´ð¤Å¤¯È󾮺Ù˦ÇÙ´â½Ñ¸åÊä½õÎÅË¡¤ÎÍÍÑÀ ¢¡ | Êü¼ÍÀþ´ØÏ¢ ¾ |
 |
 | EwingÆù¼ð¡¡¡¦¡¦¡¦Èæ³ÓŪ¤Þ¤ì¤Ê¼ðáç¤Î¿ÇÃǤȼ£ÎŶ¡¦¡¦ ¢¡ | Æù¼ð ¾ |
 |
 | EwingÆù¼ð¤Î¼£ÎÅ¡¡¡¦¡¦¡¦²¤ÊƤˤª¤±¤ëɸ½àŪ²½³ØÎÅË¡¤È¼£ÎÅÀ®ÀÓ
¶É½êÎÅË¡¡Ê³°²ÊÎÅË¡¡¦Êü¼ÍÀþÎÅË¡¡Ë¡¡
¤ï¤¬¹ñ¤Ë¤ª¡¦¡¦ ¢¡ | £´·îÂ裱½µ¡§£²Æü¡ÊÅÚ¡Ë Â¾ |
 |
 | Examestane¤¬Ãø¸ú¤·¤¿ºÆÈ¯Æý´â¤Î1Îã ¢¡ | ÇÙ´â ¾ |
 |
 | Exemestane¤¬Í¸ú¤Ç¤¢¤Ã¤¿AnastrozoleÂÑÀÆý´â¤Î1Îã | 31-12 |
 |
 | Exemestane¤Î·ò¾ïÊķиå½÷À¤Ë¤ª¤±¤ëñ²óÅêÍ¿»î¸³ ¢¡ | Æý´â ¾ |
 |
 | Exemestane¤Î·ò¾ïÊķиå½÷À¤Ë¤ª¤±¤ëÈ¿Éü·Ð¸ýÅêÍ¿»î¸³ ¢¡ | Æý´â ¾ |
 |
 | ExemestaneñÆÈÅêÍ¿¤Ë¤è¤êÃø¸ú¤òÆÀ¤¿ÇÙ¡¦¶»Ë잰ܤòȼ¤Ã¤¿¹âÎð¼Ô¿Ê¹ÔÆý´â¤Î1Îã ¢¡ | Æý´â ¾ |
 |
 | FAP¤ª¤è¤ÓGemcitabine+UFT¤¬ÁÕ¸ú¤·¤¿ÀÚ½üÉÔǽ¿Ê¹ÔÃÀǹ´â¤Î1Îã ¢¡ | ÃÀÆ»´â ¾ |
 |
 | FDG-PET ¤Ë¤è¤ëƬðôÉô¼ðáç ¿ÇÃÇ¡¡¡¦¡¦¡¦PET¸¡ºº¤Î¼ÂºÝ
ƬðôÉô´â¿ÇÃÇ
¹Ã¾õÁ£´â¿ÇÃÇ¡¦¡¦ ¢¡ | ƬðôÉô ¾ |
 |
 | FDG-PET, Receptor Imaging | 76 |
 |
 | FDG-PET¤¬°ì²áÀ´ÎưÃíºÉÀòÎÅË¡¤Î¸ú²ÌȽÄê¤ËÍÍѤȻפï¤ì¤¿Ä¾Ä²´â´Îž°Ü¤Î1Îã ¢¡ | ž°ÜÀ´Î¡´â ¾ |
 |
 | FDG-PET¤¬¿ÇÃǤËÍÍѤǤ¢¤Ã¤¿°ÀÊ¢ËìÃæÈé¼ð¤Î1Îã ¢¡ | £¸·î£±Æü ¾ |
 |
 | FDG-PET¤Ç½¸ÀÑж¿Ê¤òǧ¤á¤¿¿©Æ»¸¶È¯gastrointestinal stromal tumor (GIST) ¤Î1Îã ¢¡ | GIST ¾ |
 |
 | FDG-PET¤Ç¿ÇÃǤ·¤¨¤¿¸¶°øÉÂÁãÉÔÌÀ¤Î·ìÀ¶¼ðáç¥Þ¡¼¥«¡¼¹âÃͤòÀè¹Ô¤È¤·¤¿Æý´â½Ñ¸åÍñÁ㞰ܤÎ1Îã ¢¡ | 8·îÂè2½µ(5Æü¡Ë ¾ |
 |
 | FDG-PET¤òÍý²ò¤¹¤ë¤¿¤á¤Î´ðÁÃÃμ±¡¡¡¦¡¦¡¦¥Ú¥Ã¥È¤È¤Ï¡¡
PET¸¡ºº¤ÎÌò³ä¡¡
ÈïÇú¡¡
º£¸å¤Î²ÝÂê¤ÈŸ˾¡¡Ä¹½ê¡¡¼åÅÀ¡¦¡¦ ¢¡ | ²èÁü¿ÇÃÇ Â¾ |
 |
 | FDG-PET¸¡ºº¤Ç¶¯¤¤½¸ÀÑÁü¤ò¼¨¤·¤¿»ÒµÜÊ¿³ê¶Ú¼ð¤Î1Îã ¢¡ | 9·îÂ裱½µ¡Ê1Æü¡Ë ¾ |
 |
 | FDG-PET¸¡ºº¤Ë¤è¤ë¾Ã²½´ï´â¤Î¿ÇÃÇ¡¡¡¦¡¦¡¦¾Ã²½´ï´â¤Ë¤ª¤±¤ëFDG-PET¸¡ºº¤ÎÎ×¾²ÅªÍÍÑÀ¡¡
¡¡¥ê¥ó¥ÑÀáž°Ü¿ÇÃÇ¡¡±ó³Öž°Ü¿ÇÃÇ¡¡¡¦¡¦ ¢¡ | ²èÁü¿ÇÃÇ Â¾ |
 |
 | FEC(100)¤ÈWeekly Paclitaxel¿ë¼¡ÅêͿˡ¤¬ÁÕ¸ú¤·¤¿¿Ê¹ÔÆý´â¤Î1Îã ¢¡ | 2·î ¾ |
 |
 | Fixed Recurrent Tumor ¤ËÂФ¹¤ëÀç¹ü¹çÊ»¹üÈׯâ¡Á´Å¦½Ñ ¢¡ | £²·îÂ裴½µ¡§£²£µÆü¡Ê¶â¡Ë ¾ |
 |
 | FLIEÄ´ººÉ¼ÆüËܸìVersion¤Î³«È¯¡¡¡¦¡¦¡¦¡¦¡¦ | 29-02 |
 |
 | Folinate¡¦Tegafur¡¦Uracil(UFT/LV)ÎÅË¡¤¬ÁÕ¸ú¤·¤¿¿Ê¹Ô¡¦ºÆÈ¯ÂçIJ´â¤Î1Îã ¢¡ | ÂçIJ´â ¾ |
 |
 | Fourth-Line Therapy¤È¤·¤ÆBi-weekly CPT-11/CDDPÊ»ÍѲ½³ØÎÅË¡¤¬Í¸ú¤Ç¤¢¤Ã¤¿°ß´â´Îž°ÜºÆÈ¯¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | FPÎÅË¡¤Ë³¤¤¤ÆTS-1¤ÎÅêÍ¿¤Ë¤è¤Ã¤Æ½Ñ¸åÎɹ¥¤Ê·Ð²á¤ò¼¨¤·¤Æ¤¤¤ë¹âÅٿʹ԰ߴâ¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | FU·Ï¹³´âºÞ¤Ë¤ª¤±¤ë´ÊÊØ¤Ê¥ª¡¼¥À¡¼¥á¥¤¥É¼£ÎŤòÌܻؤ·¤¿Ç¢Ã楦¥é¥·¥ë¤ª¤è¤Ó¥×¥é¥º¥Þ5-FU¥¯¥ê¥¢¥é¥ó¥¹¤ÎÊ»ÍѬÄê ¢¡ | ²½³ØÎÅË¡ ¾ |
 |
 | G-CSF¤ò»ºÀ¸¤·¡¤Á£´â¤Ø¤Î°Àž²½¤òȼ¤Ã¤¿½Ä³Ö´ñ·Á¼ð¤Î1Îã ¢¡ | ÇÙ´â ¾ |
 |
 | G-CSF»ºÀ¸ ¿©Æ»¾®ºÙ˦·¿Ì¤Ê¬²½´â¤Î1Îã ¢¡ | ¿©Æ»´â ¾ |
 |
 | G-CSFÅêÍ¿Ãæ¤Ë¹âÇ®¤ª¤è¤ÓCRP¹âÃͤòǧ¤á¤¿°À¥ê¥ó¥Ñ¼ð¤Î2Îã ¢¡ | °À¥ê¥ó¥Ñ¼ð ¾ |
 |
 | Gastrointestinal Stromal Tumor ¢¡ | GIST ¾ |
 |
 | Gastrointestinal Stromal Tumor(GIST)¤ò½ä¤ëºÇ¶á¤Î¿ÊÊâ ¢¡ | GIST ¾ |
 |
 | Gastrointestinal Stromal Tumors¤Îʬ»ÒɸŪ¼£ÎÅ-ʬ»Ò¿ÇÃǤ«¤éʬ»ÒɸŪ¼£ÎŤޤÇ- ¢¡ | GIST ¾ |
 |
 | GDA-¥³¥¤¥ë¸ÇÄêË¡¤Ë¤ª¤±¤ë¦¹¦ÉÕ¤¥«¥Æ¡¼¥Æ¥ë¤òÍѤ¤¤¿ÂçIJ´â´Îž°Ü¾ÉÎã¤ËÂФ¹¤ëưÃíÎÅË¡¤Î¸¡Æ¤ ¢¡ | ž°ÜÀ´Î¡´â ¾ |
 |
 | Gefitinib for Previously Untreated Patients with¡¡Non-Small Cell Lung Cancer (NSCLC) -A Retrospective Study of 12 Patients Treated in One Institution ¢¡ | È󾮺Ù˦´â ¾ |
 |
 | Gefitinib(Iressa)¤¬ÁÕ¸ú¸åºÆÈ¯¤·¤¿È󾮺Ù˦ÇÙ´â¤Î3Îã ¢¡ | ʬ»ÒɸŪÌô ¾ |
 |
 | Gefitinib(Iressa)¤ÈÈ󾮺Ù˦ÇÙ´â ¢¡ | ʬ»ÒɸŪÌô ¾ |
 |
 | Gefitinib(Iressa)ÅêÍ¿¸å¤ËÇÙ˦½Ð·ì¤Ë¤è¤ëµÞÀ¸ÆµÛÉÔÁ´¤òÍ褷¤¿ÇÙÁ£´â¤Î1Îã ¢¡ | È󾮺Ù˦´â ¾ |
 |
 | Gefitinib¤¬Í¸ú¤Ç¤¢¤Ã¤¿ÇÙÁ£´âž°Ü¤Ë¤è¤ë´âÀÊ¢Ëì±ê¤Î1Îã ¢¡ | ÇÙ´â ¾ |
 |
 | Gefitinib¤ÎÅêÍ¿¤¬ÁÕ¸ú¤·¤¿ËýÀ¿ÕÉÔÁ´¤È¸ÆµÛÉÔÁ´¤òȼ¤¦¸¶È¯ÀÇÙ´â½Ñ¸åºÆÈ¯¤Î1¾ÉÎã ¢¡ | £²·îÂ裳½µ¡§£±£¹Æü¡ÊÅÚ¡Ë Â¾ |
 |
 | Gemcitabine Plus Cisplatin (GC)¡§A Salvage Regimen for Advanced Breast Cancer Patients Who Have Failed Anthracycline and/or Taxane Therapy | 33-06 |
 |
 | Gemcitabine ¡Ý¤³¤ì¤«¤é¤ÎÆý´â¼£ÎÅÌô ¢¡ | 8·îÂ裴½µ¡¡£²£¶Æü ¾ |
 |
 | Gemcitabine+ÄãÍÑÎÌCDDP/5-FU¤òÍѤ¤¤¿Æ°Ãí²½³ØÎÅË¡¤¬ÁÕ¸ú¤·¤¿ËµÂçÆ°Ì®¥ê¥ó¥ÑÀឰܤòȼ¤¦¿Ê¹ÔÃÀǹ´â¤Î2Îã ¢¡ | ÃÀ´Îç¹ Â¾ |
 |
 | Gemcitabine, DocetaxelÊ»ÍÑÎÅË¡¤¬ÁÕ¸ú¤·¤¿ºÆÈ¯ÍñÁã´â¤Î2Îã ¢¡ | ÍñÁã´â ¾ |
 |
 | Gemcitabine/CDDPÊ»ÍÑÎÅË¡¤¬ÁÕ¸ú¤·¤¿ç¯æṳ̀ʬ²½´â½Ñ¸åæþãÝ¥ê¥ó¥ÑÀឰܺÆÈ¯¤Î1Îã ¢¡ | ç¯æù´â ¾ |
 |
 | Gemcitabine/CDDPÊ»ÍÑÎÅË¡¤Ë¤è¤êĹ´ü´ÖSD¤ò°Ý»ý¤·¤Æ¤¤¤ëÈóÀÚ½ü¿Ê¹ÔÃÀǹ´â¤Î1Îã ¢¡ | ÃÀÆ»´â ¾ |
 |
 | Gemcitabine¡ÜVinorelbineÊ»ÍÑÎÅË¡¤¬ÍÍѤǤ¢¤Ã¤¿¹âÎð¼ÔÈ󾮺Ù˦ÇÙ´â¤Î1Îã ¢¡ | È󾮺Ù˦´â ¾ |
 |
 | Gemcitabine¤¬ÁÕ¸ú¤·¤¿ÀÚ½üÉÔǽ¿Ê¹Ôç¹´â¤Î1Îã ¢¡ | ç¹Â¡´â ¾ |
 |
 | Gemcitabine¤ÇLong NC¤È¤Ê¤ê22¤«·î¤Î̵¾É¾õ³°ÍèÄ̱¡¤¬²Äǽ¤Ç¤¢¤Ã¤¿ÈóÀÚ½üç¹´â¤Î1Îã ¢¡ | ²½³ØÎÅË¡ ¾ |
 |
 | Gemcitabine¤ÈCisplatinÊ»ÍѲ½³ØÎÅË¡¤¬ÁÕ¸ú¤·¤¿ºÆÈ¯ÇÙ´â¤Î1Îã ¢¡ | ÇÙ´â ¾ |
 |
 | Gemcitabine¤ÈVinorelbine¤ÎÊ»ÍѤ¬ÁÕ¸ú¤·¤¿80ºÐ¤ÎÀÚ½üÉÔǽÇÙÁ£´â¤Î1Îã ¢¡ | ¶»Á£¼ð ¾ |
 |
 | Gemcitabine¤Ë¤ÆQOL²þÁ±¤È±äÌ¿¤¬ÆÀ¤é¤ì¤¿¤ÓÌ¡À°À¶»ËìÃæÈé¼ð¤Î1Îã ¢¡ | ¶»Éô ¾ |
 |
 | Gemcitabine¤Ë¤è¤ëç¹´â¤Î²½³ØÎÅË¡ ¢¡ | ç¹Â¡´â ¾ |
 |
 | Gemcitabine¤ÎÉûºîÍѤȹͤ¨¤é¤ì¤ëËö¾¿ÀÉâ¼ð¤ò¹çÊ»¤·¤¿¿Ê¹Ôç¹´â¤Î1Îã ¢¡ | Éâ¼ð ¾ |
 |
 | Gemcitabine¤òÍѤ¤¤¿ç¹´â½Ñ¸åÊä½õÎÅË¡-°ÂÁ´À¤È¼£ÎÅÀ®ÀÓ- ¢¡ | ç¹Â¡´â ¾ |
 |
 | GemcitabineñÆÈÎÅË¡¤Ë¤è¤êTumor Dormancy¤ÎÆÀ¤é¤ì¤¿ÀÚ½üÉÔǽ繴â¤Î1Îã ¢¡ | ç¹Â¡´â ¾ |
 |
 | GemcitabineÅêÍ¿¤Ë¤è¤ê´Îž°Ü¤¬¾Ã¼º¤·¤¿ç¹´â½Ñ¸å´Îž°ÜºÆÈ¯¤Î1Îã ¢¡ | ç¹Â¡´â ¾ |
 |
 | GemcitabineÅêÍ¿¸å¤ÎÁýÂç¤ËÂФ·TS-1ñÆÈÅêÍ¿¤¬¸ú²ÌŪ¤Ç¤¢¤Ã¤¿¶É½ê¿Ê¹Ôç¹´â¤Î1Îã ¢¡ | 2·îÂè4½µ ¾ |
 |
 | GemcitabineưÃí¤¬ÁÕ¸ú¤·¤Æ¤¤¤ëç¹ÂÎÈøÉô´â¤Î1Îã ¢¡ | ç¹Â¡´â ¾ |
 |
 | GERD¤Ë¹çÊ»¤·¤¿¿©Æ»ÆýƬ¼ð¤Î1Îã¡¡¡¦¡¦¡¦Ï¢¡¡ºÜ¡¡¡¡°ìÅ٤ߤ¿¤é˺¤ì¤é¤ì¤Ê¤¤Æâ»ë¶ÀÁü ¡¡¡¡¡¡
µ.¾ÉÎã¡¡83ºÐ¡¡½÷À¡¡¹â·ì°µ¡¡¹â¡¦¡¦ ¢¡ | ¿©Æ»´â ¾ |
 |
 | GFPȯ¸½·Ï¤òÍѤ¤¤¿Ìȱ֥¨¥Õ¥§¥¯¥¿¡¼ºÙ˦¤ÎÀ¸ÂÎÆâÆ°Â֤θ¡Æ¤ ¢¡ | ÌȱÖÎÅË¡ ¾ |
 |
 | GIST¡Êgastrointestinal stromal tumor¡Ë¤ËÂФ¹¤ëÊ¢¹Ð¶À²¼¼ê½Ñ¡½Å¬±þ¤ÈÊýË¡ ¢¡ | GIST ¾ |
 |
 | GIST¡Êgastrointestinal stromal tumor¡Ë¤Î¸½¶· ¢¡ | GIST ¾ |
 |
 | GIST¡Êgastrointestinal stromal tumor¡Ë¤ÎͲ»ÇÈÆâ»ë¶À¿ÇÃÇ ¢¡ | GIST ¾ |
 |
 | GIST¡Êgastrointestinal stromal tumor¡Ë¤Îɸ½àŪ¼ê½ÑÎÅË¡ ¢¡ | GIST ¾ |
 |
 | GIST¡Êgastrointestinal stromal tumor¡Ë¤ÎÌȱÖÁÈ¿¥²½³Ø¤Ë¤è¤ë¿ÇÃÇ ¢¡ | GIST ¾ |
 |
 | GIST¡Êgastrointestinal stromal tumor¡Ë¤ÎÌôʪÎÅË¡ ¢¡ | GIST ¾ |
 |
 | Granulocyte-colony stimulating factor»ºÀ¸Â¿È¯°ß´â¤Î1Îã | 39-04 |
 |
 | H.pylori ÌôºÞ´¶¼õÀ»î¸³Ë¡¡¡¡¦¡¦¡¦ÌôºÞ´¶¼õÀ»î¸³¤Î¼ÂºÝ¡¡
H.pylori½ü¶ÝÎÅË¡¤Ë¤ª¤±¤ëCAM,AMPC¤Î¥Ö¥ì¥¤¥¯¥Ý¥¤¡¦¡¦ ¢¡ | ¥Ô¥í¥ê¶Ý ¾ |
 |
 | H.pylori¡¡13C-Ç¢ÁǸƵ¤»î¸³Ë¡¡¡¡¦¡¦¡¦¸¶Íý¡¡
¬Äê´ð½à¡¡
·ë²Ì¡¦¡¦ ¢¡ | ¥Ô¥í¥ê¶Ý ¾ |
 |
 | H.pylori¡¡·ìÀ¶¥Ú¥×¥·¥Î¥²¥óI/IIÈæ»î¸³ ¢¡ | ¥Ô¥í¥ê¶Ý ¾ |
 |
 | H.pylori¡¡¹³ÂάÄêË¡¡¡¡¦¡¦¡¦·ìÀ¶¹³ÂάÄêË¡¡¡
Ç¢Ãæ¹³ÂάÄêË¡¡¡
¹³ÂάÄêË¡¤ÎÌò³ä¡¡¡¦¡¦ ¢¡ | ¥Ô¥í¥ê¶Ý ¾ |
 |
 | H.pylori¡¡½ü¶ÝÎÅË¡¤ÎŬ±þ¡¡¡¦¡¦¡¦½ü¶Ý¼£ÎŤ¬´«¤á¤é¤ì¤ë¼À´µ¡¡
ÀìÌç»ÜÀߤÇH.pylori½ü¶Ý¼£ÎŤ¬´«¤á¤é¤ì¤ë¼À´µ¡¡
H¡¦¡¦ ¢¡ | ¥Ô¥í¥ê¶Ý ¾ |
 |
 | H.pylori¡¡¿·3ºÞÊ»ÍÑÎÅË¡¤ÎÍÍÑÀ¡¡¡¦¡¦¡¦¿·3ºÞÊ»ÍÑÎÅË¡¤È¥¬¥¤¥É¥é¥¤¥ó¡¡
¸ú²Ì¡¡¡¦¡¦ ¢¡ | ¥Ô¥í¥ê¶Ý ¾ |
 |
 | H.pylori¡¡¿×®¥¦¥ì¥¢¡¼¥¼»î¸³¡¡¡¦¡¦¡¦¿×®¥¦¥ì¥¢¡¼¥¼»î¸³¤Î»ÔÈÎ¥¥Ã¥È¡¡
ÆÃħ¡¡
¿·¤·¤¤¿×®¥¦¥ì¥¢¡¼¥¼»î¸³¡¦¡¦ ¢¡ | ¥Ô¥í¥ê¶Ý ¾ |
 |
 | H.pylori¡¡Æâ»ë¶À²¼À¸¸¡Ë¡¡¡¡¦¡¦¡¦H.pylori¶À¸¡Ë¡¤Î°ìÈÌÃí°Õ»ö¹à¡¡
H.pylori´¶À÷°ßÇ´Ëì¤Ëǧ¤á¤é¤ì¤ëÉÂÍýÁÈ¿¥¡¦¡¦ ¢¡ | ¥Ô¥í¥ê¶Ý ¾ |
 |
 | H.pylori¡¡ÇÝÍܸ¡ºº¡¡¡¦¡¦¡¦H.pylori¤ÎÀ¸Êª²½³ØÅªÀ¾õ¡¡
¸¡ÂκμèË¡¡¢Êݸˡ¡¡
ÇÝÍÜË¡¤Î¼ÂºÝ¡¡
ÇÝÍÜË¡¤Î¡¦¡¦ ¢¡ | ¥Ô¥í¥ê¶Ý ¾ |
 |
 | H.pylori´¶À÷¤ÈK-ras°äÅÁ»Ò¤Î´ØÍ¿ ¢¡ | ¥Ô¥í¥ê¶Ý ¾ |
 |
 | H.pylori´¶À÷¾É¤ÎËÜË®±Ö³ØÅý·×¡¡¡¦¡¦¡¦Ìµ¾É¸õ¼Ô¤Ë¤ª¤±¤ëH.pylori¤Î´¶À÷Ψ¡¡
¼À´µ¤È¤Î´Ø¤ï¤ê
¡¡ËýÀ°à½ÌÀ°ß±ê¡¡
¡¡¡¦¡¦ ¢¡ | ¥Ô¥í¥ê¶Ý ¾ |
 |
 | H.pylori½ü¶Ý¸å¤Î½ôÌäÂê¤ÈÂкö¡¡¡¦¡¦¡¦¤Ó¤é¤ó¡¡ÄÙáç¡¡¿©Æ»±ê¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡ | ¥Ô¥í¥ê¶Ý ¾ |
 |
 | H.pylori½ü¶Ý¼£ÎŸå¤Î´¶À÷¿ÇÃÇ¡¡¡¦¡¦¡¦µ¶ÍÛÀ¡¦µ¶±¢À¤Î¾¯¤Ê¤¤½ü¶ÝȽÄ꤬ɬÍפǤ¢¤ë¡£¡¡
´¶À÷¿ÇÃÇË¡¤ÎÆÃħ¤òÃΤ롡
½ü¶ÝȽÄê»þ¡¦¡¦ ¢¡ | ¥Ô¥í¥ê¶Ý ¾ |
 |
 | H.pylori½ü¶Ý¼£ÎÅÉÔ±þÎã¤ÈºÆ½ü¶Ý¼£ÎŤÎÊýË¡ÏÀ ¢¡ | ¥Ô¥í¥ê¶Ý ¾ |
 |
 | H.pylori½ü¶ÝÎÅË¡¤Î¸½¾õ¤Èº£¸å¤ÎÌäÂêÅÀ- ÆÃ¤Ë°ß´â¤òÃæ¿´¤Ë¤·¤Æ ¢¡ | ¥Ô¥í¥ê¶Ý ¾ |
 |
 | HCV¥³¥¢°äÅÁ»Ò¥È¥é¥ó¥¹¥¸¥§¥Ë¥Ã¥¯¥Þ¥¦¥¹¤ò¥â¥Ç¥ë¤È¤¹¤ë´Îȯ´âµ¡½ø¤Î¹Í¤¨Êý ¢¡ | ´Î±ê ¾ |
 |
 | Heat shock protein70·ë¹çÃÁÇò¼Á(HspBP1)¤Î¥¢¥Ý¥È¡¼¥·¥¹Í¶Æ³Â¥¿Ê¸ú²Ì ¢¡ | ʬ»ÒɸŪÌô ¾ |
 |
 | Helicobacter pylori ½ü¶Ý¤ÎÌäÂêÅÀ ¢¡ | ¥Ô¥í¥ê¶Ý ¾ |
 |
 | Helicobacter pylori´¶À÷¤È´ØÏ¢¼À´µ ¢¡ | ¥Ô¥í¥ê¶Ý ¾ |
 |
 | Helicobacter pylori¶Ý¤È¥«¥ÓÆÇÁǤˤè¤ë°ßȯ´âµ¡¹½¤Ë´Ø¤¹¤ëºÇ¿·¸¦µæ ¢¡ | ¥Ô¥í¥ê¶Ý ¾ |
 |
 | helicobacter pylori½ü¶Ý¤Ë¤è¤ê¾ÃÂष¤¿´â²½²á·ÁÀ®À°ß¥Ý¥ê¡¼¥×¤Î1Îã ¢¡ | ¥Ô¥í¥ê¶Ý ¾ |
 |
 | Helicobacter pylori½ü¶ÝȽÄê¤Ë¤ª¤±¤ë13C-Ç¢ÁǸƵ¤»î¸³¤ÎÍÍÑÀ¤ÈÌäÂêÅÀ ¢¡ | ¥Ô¥í¥ê¶Ý ¾ |
 |
 | Helicobaster pylori´¶À÷¤È°ß´â¤ÎÁÈ¿¥È¯À¸ ¢¡ | ¥Ô¥í¥ê¶Ý ¾ |
 |
 | HER-2/neuȯ¸½¡¦Trastuzumab»ÈÍѤÈǾž°Üȯ¾É¤È¤Î´ØÏ¢°ìž°Ü¡¦ºÆÈ¯Æý´â141ÎãÃæÇ¾Å¾°Ü38Îã¤Î²òÀϤ«¤é ¢¡ | Æý´â ¾ |
 |
 | HER2²á¾êȯ¸½¤òÄ褹¤ëž°ÜÀÆý´â¤ËÂФ¹¤ëDocetaxel¤ÈTrastuzumab Ê»ÍÑÎÅË¡¤Î¸¡Æ¤ ¢¡ | £··îÂ裳½µ¡§£±£¶Æü¡ÊÅÚ¡Ë Â¾ |
 |
 | Herceptin(R)¤È¼£ÎÅÀïά¡¡¡¦¡¦¡¦¥Ï¡¼¥»¥×¥Á¥ó¡¡¥Í¥ª¥¢¥¸¥å¥Ð¥ó¥ÈÎÅË¡¡¦¡¦ ¢¡ | Æý´â ¾ |
 |
 | High¡¡Risk¹ü¿ñ°Û·ÁÀ®¾É¸õ·²¤ËÂФ¹¤ëÄãÍÑÎÌMelphalanÆâÉþÎÅË¡ ¢¡ | ¹ü¿ñ°Û·ÁÀ®¾É¸õ·² ¾ |
 |
 | HLA-A24¹´Â«ÀHER2¥¨¥Ô¥È¡¼¥×ƱÄê¤È´â¥ï¥¯¥Á¥óÎÅË¡ ¢¡ | °ß´â ¾ |
 |
 | HLA-A24¹´Â«ÀHER2ͳÍèCTL¥¨¥Ô¥È¡¼¥×ƱÄê¤È´â¥ï¥¯¥Á¥óÎÅË¡ ¢¡ | ÌȱÖÎÅË¡ ¾ |
 |
 | Hodgkin¥ê¥ó¥Ñ¼ð¤Îʬ»ÒÉÂÍý¡¡¡¦¡¦¡¦¿·¤·¤¤¥ê¥ó¥Ñ¼ð¤ÎʬÎप¤è¤Ó¼£ÎÅ
HL¤Îʬ»Ò¥ì¥Ù¥ë¤Ç¤ÎÉÂÂ֤κǿ·Ã諤òÃæ¿´¤Ë²òÀâ¡£¡¡¡¦¡¦ ¢¡ | °À¥ê¥ó¥Ñ¼ð ¾ |
 |
 | Homer¾É¸õ·²,²£³Ö¿À·ÐËãáڤȾåÂçÀÅÌ®¾É¸õ·²¤òÍ褷¤¿·ÛÉô¾å½Ä³Ö¸¶È¯¤Î¿À·Ð²ê¼ð¤Î1Æý»ùÎã ¢¡ | £¹·îÂ裵½µ¡Ê£³£°Æü¡Ë ¾ |
 |
 | HPC-adriamycin¤Îç¯æùÆâÃíÆþÎÅË¡¤ËÊ»ÍѤ·¤¿¥Ï¥¤¥Ñ¡¼¥µ¡¼¥ß¥¢¤Ë¤è¤ê´°Á´´²²ò¤ò¤ß¤¿ç¯æù´â¾ÉÎã ¢¡ | ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² ¾ |
 |
 | HPLC¤Ë¤è¤ëUracil,Dihydrouracil,5-Fluorouracil¤ª¤è¤Ó5-Fluoro-5,6-DihydrouracilÇ»Å٤άÄê ¢¡ | ²½³ØÎÅË¡ ¾ |
 |
 | Human Orotate Phosphoribosyl Transferase¹³ÂΤκîÀ½¤È¤½¤Î±þÍÑ ¢¡ | ²½³ØÎÅË¡ ¾ |
 |
 | HypertherÐia alone or with low dose of chemotherapy in treatment of advanced breast cancer:Caser eport. ¢¡ | 15-Supplement¡¡µ ¾ |
 |
 | Ia´üFIGOʬÎà¤È¤½¤Î¼è¤ê°·¤¤¡¡¡Ý»ÒµÜðô´â ¢¡ | £¸·îÂè1½µ(£¶Æü¡Ë ¾ |
 |
 | IFN/CsAÎÅË¡¡¡¡¦¡¦¡¦¥µ¥¤¥¯¥í¥¹¥Ý¥ê¥ó£Á¤È¥¦¥£¥ë¥¹À´Î±ê¡¡
HCV°Ê³°¤Î¥¦¥£¥ë¥¹¤ËÂФ¹¤ë¥µ¥¤¥¯¥í¥¹¥Ý¥ê¥ó¤Î±Æ¡¦¡¦ ¢¡ | ´Î±ê ¾ |
 |
 | IFN/ribavirin¤ÎÊ»ÍѸú²Ì¡¡¡¦¡¦¡¦¥ê¥Ð¥Ó¥ê¥ó¤ÎºîÍѵ¡½ø¡¡
¥ê¥Ð¥Ó¥ê¥ó¤ÎñÆÈÅêÍ¿¡¡
IFN¤È¥ê¥Ð¥Ó¥ê¥ó¤ÎÊ»ÍѸú²Ì¡¡¡¦¡¦ ¢¡ | ´Î±ê ¾ |
 |
 | IFN¼£ÎŸå̵¾É¸õÀ¥¥ã¥ê¥¢¤È¤Ê¤Ã¤¿C·¿ËýÀ´Î±ê±ê ¢¡ | ´Î±ê ¾ |
 |
 | III´üÇÙ´â¤Î¼ê½ÑÀ®ÀÓ¤Èɾ²Á ¡ÝÇÙ´â¤Î³ÈÂç¼ê½Ñ¤È½Ì¾®¼ê½Ñ°ì¤½¤Îɾ²Á¤ÈŸ˾ | 106-06 |
 |
 | Imatinib¡¡¡¦¡¦¡¦¥¤¥Þ¥Á¥Ë¥Ö¡¦¡¦ ¢¡ | ʬ»ÒɸŪÌô ¾ |
 |